FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On February 24, 2017, FibroGen, Inc.’s subsidiary, FibroGen (China) Medical Technology Development Co., Ltd., entered into a Land Use Right Grant Agreement with the Bureau of Land and Resources of Cangzhou, China for approximately 33,000 square meters of land in the Cangzhou Coastal Port Economic and Technological Development Zone. We currently intend to build a 5,500 square meter commercial manufacturing facility for roxadustat drug substance for the China market. Roxadustat is our HIF prolyl hydroxylase inhibitor currently in Phase 3 development for the treatment of anemia associated with chronic kidney disease. The term of the land grant is 50 years and the one-time fee is approximately $700,000 USD.

The foregoing description of the Land Use Right Grant Agreement is not a complete description of the agreement and is qualified in its entirety by reference to the full text of the Land Use Right Grant Agreement, which will be filed with the Securities and Exchange Commission as an exhibit to FibroGen, Inc.’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2017.

About FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

FibroGen, Inc. (NASDAQ:FGEN) Recent Trading Information

FibroGen, Inc. (NASDAQ:FGEN) closed its last trading session down -0.45 at 25.20 with 713,461 shares trading hands.